Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1171-1176

  Wu, Yu ^a,b   Zhang, Xian ^a,b   Lin, Li ^a,b   Ma, Xiao Ping ^a,b   Ma, Ying Chun ^b   Liu, Pei Shu ^a  

^a SHANDONG UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Hypermethylation; Plasma; RASSF2A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; MESSENGER RNA; RASSF2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BIOSYNTHESIS; BLOOD; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PROMOTER REGION; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84896862318     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1171     Document Type: Article

References (39)

1. Agathanggelous A, Honorio S, Macartney DP, et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-18.
2. Akino K, Toyota M, Suzuki H, et al (2005). The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology, 129, 156-69.
3. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al (2003). Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 189, 1120-7.
4. Bhagat R, Chadaga S, Premalata CS, et al (2012). Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell Oncol, 35, 473-9.
5. BonDurant AE, Huang Z, Whitaker RS, et al (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol, 123, 581-7.
6. Cannistra SA. (1993). Cancer of the ovary. N Engl Med, 329, 1550-9.
7. Choi YL, Kang SY, Shin YK, et al (2006). Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch, 448, 331-6.
8. Costello JF, Plass C. (2001). Methylation matters. J Med Gent, 38, 285-303.
9. Dammann R, Li C, Yoon JH, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9.
10. Dammann R, Yang G, Pfeifer GP. (2001). Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res, 61, 3105-9.
11. Darehdori AS, Dastjerdi MN, Dahim H, et al (2012). Lack of significance of the BRCA2 promoter methylation status in different genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran. Asian Pac J Cancer Prev, 13, 1833-6.
12. Dong YQ, Liang JS, Zhu SB, et al (2013). Effect of 5-aza-2'-deoxycytidine on cell proliferation of non-small cell lung cancer cell line A549 cells and expression of the TFPI-2 gene. Asian Pac J Cancer Prev, 14, 4421-6.
13. Endoh M, Tamura G, Honda T, et al (2005). RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer, 93, 1395-9.
14. Herman JG, Baylin SB. (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349, 2042-54.
15. Hesson LB, Wilson R, Morton D, et al (2005). CpG island promoter hypermethylation of a novel Ras effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutuation. Oncogene, 24, 3987-94.
16. Ibanez de Caceres I, Battagli C, Esteller M, et al (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-81.
17. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell, 128, 683-92.
18. Jones PA, Laird PW. (1999). Cancer epigenetics comes of age. Nat Genet, 21, 163-7.
19. Leon SA, Shapiro B, Sklaroff DM, et al (1997). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res, 37, 646-50.
20. Liao X, Siu MK, Chan KY, et al (2008). Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carciongenesis. Int J Cancer, 123, 296-302.
21. Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24.
22. Makarla PB, Saboorian MH, Ashfaq R, et al (2005). Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res, 11, 5365-9.
23. Ma L, Guo Q, Ma Y, et al (2009). Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Eur J Gynaecol Oncol, 30, 370-4.
24. Maruyuma R, Akino K, Toyata M, et al (2008). Cytopalsmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis, 29, 1312-8.
25. Mutskov VJ, Farrell CM, Wade PA, et al (2002). The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev, 16, 1540-54.
26. Park HW, Kang HC, Kim IJ, et al (2007). Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer, 120, 7-12.
27. Perlin E, Moquin RB. (1972). Serum DNA levels in patients with malignant disease. Am J Clin Pathol, 58, 601-2.
28. Qiu H, Zhu J, Yu J, et al (2011). SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev, 12, 791-5.
29. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-31.
30. Ren J, He W, Zhang R, et al (2009). RASSF2A promoter methylation in hepatitis B virus-related hepatocellular cancinogenesis and its correlation with elevated serum α-fetoprotein level. J Huazhong Univ Sci Technol [Med Sci], 29, 309-12.
31. Richter AM, Pfeifer GP, Dammann RH. (2009). The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta, 1796, 114-28.
32. Schlaerth AC, Chi DS, Poynor EA, et al (2009). Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer, 19, 1199-204.
33. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. 2012. CA Cancer J Clin, 62, 10-29.
34. Spandidos DA, Sourvinos G, Tsatsanis C, et al (2002). Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int J Oncol, 21, 237-41.
35. Vos MD, Ellis CA, Elam C, et al (2003). RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol Chem, 278, 28045-51.
36. Wei SH, Balch C, Paik HH, et al (2006). Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res, 12, 2788-94.
37. Yoon JH, Dammann R, Pfeifer GP. (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer, 94, 212-7.
38. Zhang Z, Sun D, Van do N, et al (2007). Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer, 120, 32-8.
39. Zhang Q, Hu G, Yang Q, et al (2013). A multiple methylationsepcific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol, 4, 01-8.